{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-041660","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.933773+00:00","generated_at":"2026-06-29T21:44:34.054924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Medical Q2 revenue $20.7M (+167% YoY); raises FY2021 guidance to $90-95M","bullets":["Revenue $20.7M, up 167% from $7.7M in Q2 2020; gross margin improved to 80.9% from 73.1%.","Net loss of ($5.1M) or ($0.10) per share, compared to ($2.1M) loss a year ago.","Cash and equivalents $119.6M, including $107.6M from April 2021 IPO.","FY2021 revenue guidance raised to $90-95M (57-65% growth) from prior $87-92M.","ALIGN3D clinical study shows positive radiographic and patient-reported outcomes from 6 weeks to 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-041660","json":"https://secwatch.observer/filing/0001564590-21-041660.json","markdown":"https://secwatch.observer/filing/0001564590-21-041660.md","text":"https://secwatch.observer/filing/0001564590-21-041660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/0001564590-21-041660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/tmci-8k_20210805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:44:34.054924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}